Skip to Main Content
Diseases of the Digestive System - Liver, Phase III

A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis (NATiV3)

What is the purpose of this trial?

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3.

  • Trial with
    Inventiva Pharma
  • Ages
    18 years and older
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Joseph Lim

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    07/23/2024
  • Study HIC
    #2000030905